This Ad5-CEA virotherapy was reported for patients with metastatic colorectal cancer, and CEA-directed T cell responses were elicited, resulting in an 11-month overall survival advantage [56]. This evidence concerns the gene CEACAM5 and metastatic colorectal cancer.